Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The transcriptional profile of extracellular vesicles extracted from cerebrospinal flood in patients with multiple system atrophy, Parkinson's disease, amyotrophic lateral sclerosis

ABSTRACT: Extracellular vesicles (EVs) play a role in intercellular communication by transferring proteins and/or transcripts. The profile of proteins and/or transcripts in EVs may differentiate multiple system atrophy (MSA) from Parkinson's disease. In the present study, we performed transcriptome analysis of EVs extracted from cerebrospinal flood of patients with multiple system atrophy, Parkinson's disease, amyotrophic lateral sclerosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE281597 | GEO | 2025/12/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The transcriptional profile of extracellular vesicles extracted from cerebrospinal flood in patients with multiple system atrophy, Parkinson's disease, amyotrophic lateral sclerosis

Project description:The transcriptional profile of extracellular vesicles extracted from cerebrospinal flood in patients with multiple system atrophy, Parkinson's disease, amyotrophic lateral sclerosis

| PRJNA1184771 | ENA

Effects of neuron-derived a-synuclein in oligodendrocytes [scRNA-Seq]

Project description:Synucleinopathies, including multiple system atrophy (MSA) and Parkinson's disease (PD), are characterized by intracellular accumulation of α-synuclein (αSyn) aggregates. Despite oligodendrocytes' low expression of αSyn, αSyn aggregates in MSA cause glial cytoplasmic inclusions (GCIs). Here, we show that GCI development is facilitated by αSyn propagation from neurons to oligodendrocytes via Toll-like receptor 2 (TLR2). Demyelination-related characteristics in MSA oligodendrocytes and experimental models were identified by transcriptome studies. NM-101 treatment reversed the demyelination phenotype in the transgenic mouse model. These results point to anti-TLR2 immunotherapy as a possible MSA disease-modifying strategy.

2025-12-10 | GSE312642 | GEO

Effects of neuron-derived a-synuclein in oligodendrocytes [RNA-Seq]

2025-12-10 | GSE312641 | GEO

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 6

Project description:Background: Microarray technology may offer a new opportunity to gain insight into disease-specific global protein expression profiles. The present study was performed to apply a serum cytokine-array to screen for potential molecular biomarkers for Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Methodology/Principal Findings: Serum samples were obtained from patients with clinical diagnoses of PD (n=117), MSA (n=31) and PSP/CBS (n=38) and 99 controls. Cytokine profiles of sera of patients and controls were analyzed with a semiquantitative human cytokine antibody array. In a next step, significantly altered cytokines were individually validated by immunoassays. The cytokine array revealed a significantly altered expression of 12 cytokines. Immunoassay validation confirmed a significant increase of PDGF-BB in PSP/CBS, MSA and PD and a decrease of Prolactin in PD (Kruskal-Wallis p<0.05). A multivariate analysis taking into account diagnoses anti-Parkinsonian treatment, sex and age revealed that PDGF-BB levels were influenced only by the diagnoses (p<0.001), whereas Prolactin levels were influenced only by anti-Parkinsonian treatment (p<0.001). These findings could be corroborated by a subgroup analysis in untreated patients. Conclusions/Significance: In our unbiased cytokine array screening approach we found PDGF-BB to be elevated in PSP/CBS, MSA and PD. Increased PDGF-BB levels might be of relevance in a model of molecular biomarkers for Parkinsonian syndromes. Screen serum samples from patients with Parkinson's disease, progressive supranuclear palsy, corticobasal syndrome, multisystem atrophy and controls for deregulation of serum proteins using a cytokine-array detecting 174 secreted signaling proteins.

2011-11-23 | E-GEOD-32037 | biostudies-arrayexpress

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 8

2011-11-23 | E-GEOD-32040 | biostudies-arrayexpress

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 7

2011-11-23 | E-GEOD-32039 | biostudies-arrayexpress

Distinct microglia subsets are associated with α-synucleinopathy in multiple system atrophy

Project description:We developed a novel mice model of multiple system atrophy (MSA)-cerebellar type (MSA-C) by over-expression of human mutant α-synuclein (α-syn) in oligodendrocyte using Tet-off system. We identified distinct microglial subpopulations in a novel MSA-C model mice.

2022-09-06 | GSE209944 | GEO

mRNA microarray analysis of the substantia nigra in a mouse model of multiple system atrophy

Project description:Multiple system atrophy (MSA) is a fatal rapidly progressive Î±-synucleinopathy, characterized by prominent Î±-synuclein accumulation in oligodendrocytes. In this study we investigated mRNA expression in substantia nigra of MSA transgenic mice (Tg(Plp1-SNCA)1Haa) and wild type controls. This forms part of a larger study in which we investigated miRNA-mRNA regulatory network in substantia nagra and striatum of MSA transgenic mice in pre-motor stage of neurodegenration.

2016-03-15 | E-MTAB-3985 | biostudies-arrayexpress

Identification of novel cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach

Project description:The aim of our study was to investigate cerebrospinal fluid (CSF) tryptic peptide profiles as potential diagnostic biomarkers for the discrimination of parkinsonian disorders. CSF samples were collected from individuals with parkinsonism, who had an uncertain diagnosis at the time of inclusion and who were followed for up to 12 years in a longitudinal study. We performed shotgun proteomics to identify tryptic peptides in CSF of Parkinson’s disease (PD, n=10), multiple system atrophy patients (MSA, n=5) and non-neurological controls (n=10). We validated tryptic peptides with differential levels between PD and MSA using a newly developed selected reaction monitoring (SRM) assay in CSF of PD (n=46), atypical parkinsonism patients (AP; MSA, n=17; Progressive supranuclear palsy; n=8) and non-neurological controls (n=39). We identified 191 tryptic peptides that differed significantly between PD and MSA, of which 34 met our criteria for SRM development. For 14/34 peptides we confirmed differences between PD and AP. These tryptic peptides discriminated PD from AP with moderate-to-high accuracy. Random forest modelling including tryptic peptides plus either clinical assessments or other CSF parameters (neurofilament light chain, phosphorylated tau protein) and age improved the discrimination of PD vs. AP. Our results show that discovery of tryptic peptides by untargeted and subsequent validation by targeted proteomics is a suitable strategy to identify novel potential CSF biomarkers for PD versus AP. Furthermore, the tryptic peptides, and corresponding proteins, that we identified as differential biomarkers may increase our current knowledge about the disease-specific pathophysiological mechanisms of parkinsonism.

2022-02-16 | PXD028842 | Pride

microRNA profiling by high-throughput sequencing in the substantia nigra and striatum of Multiple System Atrophy (MSA) transgenic mice and wild type controls

Project description:Multiple system atrophy (MSA) is a fatal rapidly progressive Ia-synucleinopathy, characterized by prominent Ia-synuclein accumulation in oligodendrocytes. In this study we investigated miRNA expression in the substantia nigra and striatum of MSA transgenic mice (Tg(Plp1-SNCA)1Haa) and wild type controls. This forms part of a larger study in which we investigated miRNA-mRNA regulatory network in substantia nigra and striatum of MSA transgenic mice in pre-motor stage of neurodegenration.

2016-03-15 | E-MTAB-3993 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data